Cite
HARVARD Citation
Eggermont, A. et al. (n.d.). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet oncology. 16 (5), pp. 522-530. [Online].